Clément O, Siauve N, Lewin M, de Kerviler E, Cuénod C A, Frija G
Service de Radiologie, Hôpital Laënnec, Paris, France.
Biomed Pharmacother. 1998;52(2):51-8. doi: 10.1016/S0753-3322(98)80003-6.
New contrast agents are being developed by drug companies to better image the liver magnetic resonance imaging (MRI). They can be divided into hepatobiliary agents (Gd-EOB-DTPA, Gd-BOPTA, Mangafodipir) and nanoparticulate agents directed to the reticulo-endothelial system (ferumoxides, SHU 555A). After intravenous injection, all these agents concentrate in the liver and induce profound signal changes. Particulate agents induce predominantly a darkening of the liver parenchyma, while hepatobiliary agents induce a brightening. In both cases, liver-lesion conspicuity is enhanced, leading to a better visualization of the lesion. After a description of the principal pharmacokinetic characteristics of the compounds, this review paper summarizes the utility of the agents in the detection and characterization of focal liver diseases.
制药公司正在研发新型造影剂，以更好地对肝脏进行磁共振成像（MRI）。它们可分为肝胆造影剂（钆塞酸二钠、钆布醇、锰福地匹三钠）和靶向网状内皮系统的纳米颗粒造影剂（铁氧化物、SHU 555A）。静脉注射后，所有这些造影剂都会在肝脏中聚集并引起显著的信号变化。颗粒造影剂主要导致肝实质变暗，而肝胆造影剂则导致肝实质变亮。在这两种情况下，肝脏病变的显影都得到增强，从而能更好地观察到病变。在描述了这些化合物的主要药代动力学特征后，本文综述了这些造影剂在局灶性肝病检测和特征描述中的应用。
